Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | PF-07826390 |
| Trade Name | |
| Synonyms | PF 07826390|PF07826390 |
| Drug Descriptions |
PF-07826390 is a bispecific antibody that targets LILRB1 and ILT4 (LILRB2), which potentially results in reduced ILT4 (LILRB2)- and ILT2-dependent immune suppression and enhanced antitumor immune response (NCI Drug Dictionary). |
| DrugClasses | LILRB2 Antibody 12 |
| CAS Registry Number | NA |
| NCIT ID | C209282 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| PF-06801591 + PF-07826390 | PF-06801591 PF-07826390 | 0 | 1 |
| PF-07826390 | PF-07826390 | 0 | 1 |